HOT STOCKS / A Stock To Own TODAY !
 
 
Apri-Mayl 2010
 
HOT STOCKS
 
In
This Issue
 
MNTR
$2.25 Short Term Price Target
 
 
Stocks on the Move
 
 
 
 
Stock of the Day:
Priceline.com Inc.
Priceline.com Inc (PCLN)
 
 
See This Report
 
 
 
 
 
 
DEAR SUBSCRIBER ,
You are receiving this email because you have signed up for daily trading information on only the best emerging companies.  If you do not wish to receive Hot Stock Companies delivered daily to your inbox, please unsubscribe below and we will respect you wishes.  Thank you for your membership and we look forward to MAKING YOU MONEY !
 
Respectfully,
Fred Ballou , Editor in Chief  , Hot Stocks

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

 

 
Little-Dendreons Share Stunning Gains Across Mentor Capital Cancer Immunotherapy Index on FDA Approval of Provenge Using the Common Immunotherapy Process Pioneered by Dendreon for Prostate Cancer

2010-04-30 13:03 ET - News Release


Company Website: http://mentorcapital.com/
SAN DIEGO -- (Business Wire)

Mentor Capital, Inc. (Pink Sheets:MNTR) reports a 10% average one-day gain in the 10 trading companies of the Mentor Capital Cancer Immunotherapy Index led by yesterday's 36.65% one-day price appreciation of Index pioneer and market leader, Dendreon (NASDAQ:DNDN). The extraordinary Dendreon price appreciation follows from the announcement of the FDA approval of Dendreon's Provenge immunotherapy treatment for prostate cancer. Every other company in the Cancer Immunotherapy Index was also in the green because they use similar and sometimes identical processes to treat other cancers.

Different cancers express different surface proteins. Dendreon trained the patient's immune system to target PAP which is over-expressed in most prostate cancers. Through FDA authorized testing, Dendreon showed that an immune system activated to attack prostate cancer can be a safe and effective cancer treatment. Dr. Phillip Kantoff, Chief Clinical Research Officer at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School summarizes the positive future for treatment of all cancer types that the Dendreon approval implies, "Cancer immunotherapies that use the patient's own immune system will likely create an entirely new treatment paradigm with cancer."

Cancer Immunotherapy Index creator and Mentor Capital, CEO, Chet Billingsley, explains the investor reaction, "Drendreon's FDA approval greatly reduces perceived financial risk and uncertainty across the entire cancer immunotherapy space. The immune system is common in all therapies. If the cancer surface protein is carefully selected by different Index companies for different cancers, then there is no reason to believe similar cancer immunotherapy treatments would not then be similarly safe, effective and, in due course, approved. This would lead to several Dendreon-sized immunotherapy markets for the other cancer types. The companies with a significant lead in the race to secure FDA approval for those treatments in the new major cancer markets are today's leaders of the Cancer Immunotherapy Index."

The Mentor Capital Cancer Immunotherapy Index companies and their reported one-day gain on the Dendreon FDA approval announcement follow: Dendreon +36.65%, Immunocellular Therapuetics, Ltd. (OTCBB:IMUC) +22.88%, Oncothyreon (NASDAQ:ONTY) +4.53%, Antigenics (NASDAQ:AGEN) +7.89%, Biovest International (BVTI.PK) +9.68%, Celldex Therapeutics (NASDAQ:CLDX) +7.76%, Northwest Biotherapeutics (OTCBB:NWBO) +2.92%, Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) +0.00%, CEL – SCI Corp. (AMEX:CVM) +4.70% and Generex Biotechnology (NASDAQ:GNBT) +3.31% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, and Quantum Immunologics, Inc. a private company. Average one-day gain of trading companies: 10.03%.

Mentor Capital, Inc. invests in all companies in the Cancer Immunotherapy Index and significantly overweights its positions in those companies it views with the greatest medical and financial promise. The Index company summaries can be tracked through updates of the Cancer Immunotherapy Index presented at www.MentorCapital.com.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

Contacts:

Chet Billingsley, CEO
Mentor Capital, Inc.
 (760) 788-4700 

Source: Mentor Capital, Inc.

REMOVE MY NAME

Stonebridge.holdings.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. For continuing coverage of our highlighted stocks please sign up for our free newsletter. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. The information provided herein is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

Copyright stonebridge.holdings.com. All rights reserved. stonebridge.holdings.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. stonebridge.holdings.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act  of 1933, Section 17(b), stonebridge.holdings.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the stonebridge.holdings.com web site.  stonebridge.holdings.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as ?expects??, ?will,? ?anticipates,? ?estimates, ?believes, ? or that by statements indicating certain actions ?may,? ?could,? or ?might? occur. 

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK .Call  to contact editorial William Ballou
 954-360-9800

email:president @ financialtvcast.com

 

The Information in this Breaking News Report .  is A PAID ADVERTISEMENT and is for the viewers information only.  the company and/or a third party has agreed to pay a fee  to have this corporate information featured. The corporate information is purely and solely the responsibility of and it is neither commented upon, researched, or in any manner the responsibility of Stonebridge Media, Inc whose only function is as a supplier of media facilities. Any information provided by the advertisers of Target Publishing, Inc., through its media services, is not to be construed as a recommendation or suggestion or offer to buy or sell securities, but is provided purely as an informational media service. Target Publishing , Inc makes no warranties or undertakings as to the accuracy or completeness of this information. All due diligence should be done by the reader or their financial advisor. Investing in securities is speculative and carries risk. Persons who wish to buy or sell securities should only do so in consultation with their registered securities advisers.